GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.
IC50&Target
RIP1, RIP3
体外研究
GSK2593074A (GSK’074; 0.01, 0.1, 1, 10, and 100 nM; 6 hours for MOVAS cells; 3 hours for L929 cells) completely rescues cells from necroptosis under different stimuli in both human and murine cells at IC50~3 nM. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK2593074A inhibits necroptosis with an IC50 of ~3 nM.
Cell Viability Assay
Cell Line:
Mouse smooth muscle cell line MOVAS; Mouse fibroblast cell line L929
Concentration:
0.01, 0.1, 1, 10, and 100 nM
Incubation Time:
6 hours for MOVAS cells; 3 hours for L929 cells
Result:
Inhibited MOVAS and L929 cells with the IC50 of 3 nM.
体内研究
GSK2593074A (GSK’074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P<0.05) .
Animal Model:
Apoe female mice (9-10 months)
Dosage:
0.93 mg/kg/day; 200 µL
Administration:
Daily i.p. injection; 14 or 28 days
Result:
Inhibited aneurysm formation in mouse models of aneurysms.
分子式
C27H23N5Os
分子量
465.57
CAS号
1337531-06-2
运输条件
Room temperature in continental US; may vary elsewhere.